METHODS	Eligible patients with frequency ( > or = eight voids/24 h ) and either urgency ( > or = six episodes over 3 days ) or urgency urinary incontinence ( UUI ; > or = three episodes over 3 days ) were randomized to placebo , fesoterodine 4 or 8 mg , or tolterodine extended-release ( ER ) 4 mg for 12 weeks ; fesoterodine 4 mg data were published elsewhere .\